bringing energy to life
Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease.
Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, the company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.
Khondrion has published a scientific hypothesis on COVID-19, highlighting the potential of its lead drug candidate, sonlicromanol, currently in phase IIb development to treat a range of mitochondrial diseases, to be repurposed for the treatment of patients with severe COVID-19 disease. The company is actively searching for partners to assist in evaluating the hypothesis and the potential of bringing sonlicromanol to COVID-19 patients.
“The solution is within our reach”
Since 2012 Khondrion has been progressing a pipeline with the potential to deliver transformative medicines for patients living with mitochondrial disease.
At Khondrion, we know that working in collaboration with others is important to accelerate the development of innovative new medicines. That is why we are pursuing the newest science both within our own labs and through partnerships across an extensive clinical and academic network, exploring new avenues of science and sharing knowledge of mitochondrial disease to help develop important new treatments for patients.
get in touch
Whether you are a researcher, job seeker, health professional, patient or potential investor, you can contact us using this form.